Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: CNS Pharmaceuticals Inc. CNSP

MissionIRNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Demonstrate Effectiveness vs. Established Chemotherapy Drug in Phase 2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP) continues to aggressively pursue FDA approval for its lead drug candidate, Berubicin. The novel candidate is the first anthracycline that appears to be able to cross the blood-brain barrier to combat tumors — stepping up its … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

Patients with Incurable Brain Cancers Find New Hope in University Study, Upcoming CNS Pharmaceuticals (NASDAQ: CNSP) Clinical Trial

Glioblastoma Multiforme (often known simply as GBM) is a fatal, incurable class of brain cancers that usually leaves patients only about 15 months to live once they are diagnosedA recent study by the Washington University School of Medicine found that … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) New Investor Presentation Shows Value-Added Milestones for Berubicin in 2021

GBM is diagnosed in more than 13,000 people each year in the US, with only a 12–18-month life expectancyPotentially pivotal Phase 2 trial of Berubicin is scheduled to commence around the end of Q1 2021The company is continuing its pre-clinical … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Continues to Advance Toward Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) recently announced that the Wroclaw, Poland-based Lower Silesian Medical Chamber Ethics Committee gave WPD Pharmaceuticals (CSE: WBIO) (Frankfurt: 8SV1) (“WPD”), the company’s sublicensee in Europe and Asia for its lead drug candidate, Berubicin, a positive opinion … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP, MissionIRNewsBreaks | Leave a comment

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set to Begin Enrolling Brain Cancer Drug Trial Participants

Brain cancer drug developer CNS Pharmaceuticals is finalizing preparations to begin March enrollment of patients in its potentially pivotal Phase 2 trial evaluating its promising lead candidate, Berubicin, for the overall survival improvement of glioblastoma (“GBM”) patientsGlioblastomas are a type … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in First-Ever Emerging Growth Virtual Conference

CNS Pharmaceuticals (NASDAQ: CNSP) CEO John Climaco will be presenting at the inaugural Emerging Growth Virtual Conference. Scheduled for March 17–18, the virtual conference is presented by M Vest LLC and Maxim Group LLC. The conference agenda includes roundtable discussions … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Leverages ‘Absolute Powerhouse Compound’ as IND Status Paves Way for Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) CEO John Climaco, in a recent podcast, showed his excitement at news that the U.S. Food and Drug Administration (“FDA”) had granted Berubicin investigational new drug (“IND”) status. The IND designation clears the way for the … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP, MissionIRNewsBreaks | Leave a comment

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) and WPD Pharmaceuticals (CSE: WBIO) (Frankfurt: 8SV1) Get the Green Light for Clinical Trials’ Protocols from Ethics Panels

CNS Pharmaceuticals holds the exclusive worldwide license to the Berubicin chemical compoundBerubicin is CNSP’s lead, novel anthracycline candidate for the treatment of glioblastoma multiforme (“GBM”) that was the subject of a previously conducted Phase 1 clinical trial, which had a … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Upcoming H.C. Wainwright Global Life Sciences Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the company’s CEO, John Climaco, will present at the virtual H.C. … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP, MissionIRNewsBreaks | Leave a comment

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Optimistic About Upcoming Berubicin Trials After IND Approval

Berubicin is CNS Pharmaceuticals’ lead product candidate for treatment of Glioblastoma Multiforme, and has the potential to be the first anthracycline to cross the blood-brain barrier based on limited results from a Phase 1 trialThe market for GBM treatment is … Continue reading

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment